Evaluation of a Transdermal Drug Delivery System for Veterinary Patients
Canine osteoarthritis (OA) is a progressive degenerative disease often leading to inflammation, pain and disuse of the affected joint. Meloxicam, commonly used to manage canine OA, is given as oral tablets or suspensions, or intravenous (IV) or subcutaneous (SC) injections. However, these routes are associated with decreased owner compliance and adverse drug reactions (ADRs) with chronic use. delivra™ uses the transdermal delivery route to transport meloxicam. Meloxicam compounded in delivra™ (TDM) was investigated to evaluate i) penetration of meloxicam into canine synovial fluid (SF) and plasma, ii) stability of TDM and iii) anti-inflammatory and analgesic properties of TDM. Results demonstrated that delivra™ was able to transport meloxicam to canine SF and plasma at comparable levels to oral Metacam® suspension and meloxicam was stable in delivra™ for up to 2 months. However, initial work with TDM did not demonstrate significant anti-inflammatory or analgesic effects in a rat model of inflammation.